OCGN

Ocugen is a clinical-stage gene-therapy company whose $4.41M of FY2025 revenue is a grant/collaboration trickle, not a product business — the 112x P/S is meaningless and the story is entirely about the pipeline and the balance sheet. On the pipeline, management is genuinely advancing: OCU400 completed Phase 3 liMeliGhT enrollment with a rolling BLA slated for Q3 2026, topline data in Q1 2027 and potential approval in 2027, supported by 3-year Phase 1/2 data showing ~2-line LLVA gain in 7/8 evaluable subjects; OCU410ST is in the GARDian3 pivotal trial with a BLA targeted for H1 2027. That is a credible, catalyst-rich gene-agnostic retinal franchise with EMA ATMP classification and FDA RPDD.

The balance sheet, however, makes this uninvestable at face value. FY2025 ended with just $18.9M cash (down 67.9%) against $57.0M of operating cash burn — under four months of runway — while stockholders' equity has gone negative to -$12.2M and the accumulated deficit sits at -$408M. R&D rose 23.7% to $39.8M, so the burn is accelerating into exactly the period when cash is thin. Total liabilities ($55.7M) now exceed total assets ($43.5M). This company must raise capital imminently and repeatedly; with a $1.51 stock and 328M shares already up 12.3% YoY, that financing will be heavily dilutive equity issuance — the primary reason the shares are where they are.